EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adenovirus Vector‐Mediated In Vivo Knock‐in Treatment of Neonatal Phenylketonuria Mice Using Terminally Cleaved Donor DNA

Megumi Yamaji, Hirotaka Tabata, Mariko Nakamura, Ryoko Fuse, Tadashi Okada, Shun-Ichi Ohba, Tomokazu Ohishi iD, Manabu Kawada iD, Izumu Saito, Shigeto Sato, Tomoko Nakanishi iD

The Journal of Gene Medicine · 2026

DOI: 10.1002/jgm.70104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2026. Verfasst von Megumi Yamaji und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biomedical Research Resources, Juntendo University Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Genetic Vectors, Gene Knock-In Techniques, Adenoviridae, Phenylalanine Hydroxylase. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adenovirus vectors (AdVs) are widely used and have an advantage of large insert capacity compared with adeno‐associated virus vectors. However, AdVs have scarcely been used in genome‐editing knock‐in strategies because of low efficiency.

Methods

Novel AdVs possessing a very large, 3.7 kb donor DNA fragment and six or eight multiplex gRNA expression units were developed for CRISPR/Cas9‐mediated knock‐in to correct a phenylalanine hydroxylase ( Pah ) gene in a Pah enu2 phenylketonuria mouse model. These AdVs were co‐infected to Hepa1–6 cells or liver cells in vivo together with an AdV expressing either native Cas9 or Cas9 nickase (Cas9n) for double‐nicking cleavage.

Results

In vitro knock‐in of the AdVs carrying 3.7 kb donor DNA and six gRNA units targeting the cell genome was observed in both cases using Cas9 and Cas9n, though their efficiencies were low. Therefore, we generated AdVs carrying an additional two gRNA units that cleave the donor DNA terminus in the AdV genome via native Cas9 or Cas9 nickase. The knock‐in efficiency increased approximately twofold for both vectors and reached a maximum of 8% for native Cas9 without selection. Newborn phenylketonuria model mice were intravenously administered the knock‐in AdV together with the native‐Cas9 AdV. Although the knock‐in efficiency by homologous recombination occurred in only approximately 1% of hepatocytes, blood phenylalanine levels were reduced by up to 30%. Also, unintended fragments produced by nonhomologous end‐joining were observed between the cleavage site at the terminus of the donor DNA in the AdV genome and the target site in the cell genome.

Conclusions

The knock‐in efficiency of AdVs can be increased by cleaving the terminus of the donor DNA, although it would be desirable to avoid nonhomologous end‐joining between double‐strand break termini.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic VectorsGene Knock-In TechniquesAdenoviridaePhenylalanine HydroxylasePhenylketonuriasDNAAnimalsMiceCRISPR-Cas SystemsGenetic TherapyDisease Models, AnimalAnimals, NewbornHumansGene EditingRNA, Guide, CRISPR-Cas Systems

Stichwörter der Autor:innen

Cas9 nickaseadenovirus vector (AdV)knock‐inmultiplex gRNAphenylalanine hydroxylase (PAH)phenylketonuria (PKU)

Substanzen

Phenylalanine HydroxylaseRNA, Guide, CRISPR-Cas SystemsDNA

Autor:innen und Institutionen

  • Center for Biomedical Research Resources, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan.
  • Laboratory of Virology, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Foundation, Tokyo, Japan.
  • Department of Food Management, Okayama Gakuin University, Okayama, Japan.
  • Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Shizuoka, Japan.
  • Department of Physiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

ORCID-Profile: Tomokazu Ohishi, Manabu Kawada, Tomoko Nakanishi

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Yamaji, M., Tabata, H., Nakamura, M., Fuse, R., Okada, T., Ohba, S. I., Ohishi, T., Kawada, M., Saito, I., Sato, S., & Nakanishi, T. (2026). Adenovirus Vector‐Mediated In Vivo Knock‐in Treatment of Neonatal Phenylketonuria Mice Using Terminally Cleaved Donor DNA. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.70104

Vancouver

Yamaji M, Tabata H, Nakamura M, Fuse R, Okada T, Ohba SI, et al. Adenovirus Vector‐Mediated In Vivo Knock‐in Treatment of Neonatal Phenylketonuria Mice Using Terminally Cleaved Donor DNA. The Journal of Gene Medicine. 2026. doi:10.1002/jgm.70104

BibTeX
@article{Yamaji2026,
  author = {Yamaji, Megumi and Tabata, Hirotaka and Nakamura, Mariko and Fuse, Ryoko and Okada, Tadashi and Ohba, Shun-Ichi and Ohishi, Tomokazu and Kawada, Manabu and Saito, Izumu and Sato, Shigeto and Nakanishi, Tomoko},
  title = {Adenovirus Vector‐Mediated In Vivo Knock‐in Treatment of Neonatal Phenylketonuria Mice Using Terminally Cleaved Donor DNA},
  journal = {The Journal of Gene Medicine},
  year = {2026},
  doi = {10.1002/jgm.70104}
}
Kostenlos starten →